SanBio Company Limited (OTCMKTS:SNBIF) Sees Significant Increase in Short Interest

Posted by Chris Copeland on Mar 17th, 2026

SanBio Company Limited (OTCMKTS:SNBIF – Get Free Report) saw a large growth in short interest in the month of February. As of February 27th, there was short interest totaling 1,533,629 shares, a growth of 19.6% from the February 12th total of 1,282,295 shares. Based on an average trading volume of 0 shares, the short-interest ratio is presently ∞ days. Based on an average trading volume of 0 shares, the short-interest ratio is presently ∞ days.

Wall Street Analyst Weigh In

Separately, UBS Group assumed coverage on shares of SanBio in a research report on Sunday, December 14th. They issued a “neutral” rating for the company. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Hold”.

Check Out Our Latest Stock Report on SNBIF

SanBio Price Performance

Shares of OTCMKTS SNBIF opened at C$10.11 on Tuesday. SanBio has a 1-year low of C$4.65 and a 1-year high of C$23.00. The company has a 50-day moving average of C$10.11 and a two-hundred day moving average of C$16.72.

SanBio Company Profile

(Get Free Report)

SanBio Inc is a clinical‐stage regenerative medicine company focused on developing proprietary cell therapies to address central nervous system disorders. The company’s core technology is based on modulating the brain’s innate repair mechanisms through the transplantation of adult stem cells, with the goal of restoring neurological function in patients suffering from conditions such as stroke, traumatic brain injury and neurodegenerative diseases.

The company’s lead product candidate, SB623, is an investigational cell therapy for chronic motor deficits following ischemic stroke.